A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Inclusion Criteria:

- Subjects must have chronic, genotype 1a or 1b, hepatitis C with HCV RNA >1000 IU/mL

- Population A: HCV Peg IFN/RBV treatment naive (received no prior HCV therapy)or
Peg-IFN/RBV prior treatment with relapse

- Population B: Peg-INF/RBV prior null or partial responder

- Subjects must not have achieved SVR24 after at least 1 prior course of Peg IFN/RBV
therapy of standard duration

- Subject must have positive HIV antibody at Screening

- Subject must have a diagnosis of HIV-1 infection >6 months before Screening

- Subjects should be taking 1 of the following permissible HAART regimens for HIV
continuously for 12 weeks prior to screening:

- Atripla® or equivalent components (efavirenz, tenofovir, emtricitabine)

- Efavirenz plus Epzicom® (abacavir, lamivudine) or equivalent components

- Boosted atazanavir (atazanavir with ritonavir) plus Truvada® (tenofovir,
emtricitabine) or equivalent components

- Boosted atazanavir plus Epzicom®, or equivalent components

- Raltegravir plus Truvada®, or equivalent components

- Raltegravir plus Epzicom®, or equivalent components

- CD4 counts and HIV-1 RNA meeting acceptable criteria at Screening as specified in the
protocol.

- Laboratory values within acceptable ranges at Screening as specified in the protocol

Exclusion Criteria:

- Subjects anticipating a need to switch HAART regimens within 14 weeks after Day 1 or
any switches occurring 12 weeks prior to Day 1

- Use of azidothymidine (AZT), didanosine (ddI) or stavudine (d4T) nucleosides

- Contraindications to any planned HAART component as per the respective drug labeling
information

- Contraindications to Peg IFN or RBV

- Evidence of hepatic decompensation

- Clinical suspicion of acute hepatitis

- Any other cause of liver disease in addition to hepatitis C

- History of organ transplantation (except cornea and skin)

- Autoimmune-mediated disease

- Participated in any investigational drug study within 90 days before Day 1

- Previous treatment with an HCV protease inhibitor